Coloplast stock holds steady after strong third-quarter profit rebound
Published on 08/21/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast (ISIN DK0060448595) stock is drawing interest on August 21, 2026 as investors weigh a sharp rebound in third-quarter profit against a double-digit share-price decline since the start of the financial year. Recent reporting for the company’s 2025/2026 financial year points to an 82 percent jump in third-quarter profit to close to DKK 1.5 billion after a weak second quarter that was hit by a large write-down.
Profit rebound marks a turning point
According to financial reports released on August 21, 2026 for Coloplast’s current 2025/2026 financial year, profit in the third quarter rose 82 percent compared with the prior-year quarter to nearly DKK 1.5 billion, reversing a sharp profit decline that had been triggered by a billion-kroner write-down in the second quarter. This swing in earnings suggests that management has moved past the one-off charge and that underlying demand in ostomy care, continence care and related categories is again translating into bottom-line growth.
The contrast between the weak second quarter and the strong third quarter is particularly relevant for investors because it shows that the earlier profit pressure was not purely operational. When a single write-down drives a profit slump and the following quarter’s profit climbs by more than four-fifths, it underlines the resilience of the core business model, even if the balance sheet had to absorb a significant adjustment.
Shares lag fundamentals despite guidance hold
Market data for Coloplast’s shares traded in Europe indicate that the stock has been under pressure for much of 2026 despite the latest operational recovery. A recent Tradegate quotation showed Coloplast at EUR 57.60 with a five-day change of plus 1.46 percent but a year-to-date change of minus 19.98 percent as of August 21, 2026, signaling that the slight short-term improvement has not erased the deeper decline that started earlier in the financial year.
The five-day gain of 1.46 percent versus a year-to-date slide of 19.98 percent implies that investors have only recently started to rebuild confidence after digesting the billion-kroner write-down and the earlier profit decline. For valuation-focused shareholders, the combination of an 82 percent profit increase in the third quarter of the 2025/2026 financial year and a share price still nearly one-fifth lower since January suggests that earnings recovery has yet to be fully reflected in the stock.
Analyst expectations and long-term positioning
In addition to the rebound in reported profit, external equity research commentary on August 21, 2026 highlighted that Coloplast has recently beaten earnings expectations, with consensus estimates for earnings per share being exceeded in the latest quarter. That same analysis indicates that the average 12-month price target stands at DKK 467, which provides a numerical yardstick for how some analysts see the company’s medium-term value relative to the current share price level.
The relationship between Coloplast’s current price in the high-50s in EUR terms and a consensus target of DKK 467 is not a direct one-to-one comparison given currency and listing differences, but it still signals that the analyst community assumes upside potential if the company can sustain its improved third-quarter profit trajectory. For income-oriented investors, Coloplast’s profile as a healthcare supplier with recurring demand in ostomy and continence products may also support a premium valuation once the impact of the second-quarter write-down is fully absorbed.
Chronic-care products support recurring demand
Coloplast’s core business revolves around chronic-care medical products that patients use daily, which helps stabilize revenue even when macroeconomic conditions are volatile. Ostomy pouches and accessories play a central role here, giving patients who have undergone intestinal surgery a reliable way to manage waste collection while maintaining mobility and quality of life in everyday situations.
Alongside ostomy care, the company’s continence care segment offers catheters and related devices designed for people with bladder or urinary retention issues. These products are typically prescribed for long-term use, which can support a consistent sales base that grows in line with patient numbers and demographic trends. The combination of recurrent demand and high switching costs in these categories is one reason many investors view Coloplast as a defensive healthcare name despite the earnings volatility introduced by exceptional items such as the second-quarter write-down in the 2025/2026 financial year.
Stock valuation context
Coloplast’s listing on its home European exchange means that many international investors access the company through local shares quoted in EUR as well as through American depositary receipts that trade in USD. One recent data point for the sponsored ADR showed a price of $6.98 as of August 20, 2026, with the daily trading range spanning a low of $6.83 and a high of $6.99. While ADR prices reflect both the home-share level and the ADR ratio, the figures still provide a reference that US-based investors can use to track performance in their home currency.
The same ADR snapshot also reported that an investment of $1.50 at a price of $6.98 per ADR would correspond to 0.2149 ADR shares, highlighting how fractional-share trading allows smaller investors to gain exposure to Coloplast. When this ADR context is combined with the EUR 57.60 Tradegate quotation and the minus 19.98 percent year-to-date performance as of August 21, 2026, it reinforces the picture of a stock that has lagged despite a recent improvement in operating performance.
Outlook for the rest of the financial year
Looking ahead to the remainder of the 2025/2026 financial year, the key question for the market is whether Coloplast can translate its third-quarter profit rebound into a sustained earnings trend. An 82 percent increase in quarterly profit to nearly DKK 1.5 billion provides a strong base from which to grow, but investors will want to see confirmation that this improvement is driven not only by the absence of new write-downs but also by organic growth in core product segments.
Management’s ability to keep operating margins stable while navigating inflation, supply-chain costs and reimbursement changes in healthcare systems will be crucial for valuation. Because the share price remains down 19.98 percent since January 2026, even modest additional profit growth in the fourth quarter of the 2025/2026 financial year could support a rerating, particularly if upcoming updates confirm solid revenue growth in ostomy and continence care alongside continued control of one-off items.
